Status:
UNKNOWN
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
7-80 years
Phase:
EARLY_PHASE1
Brief Summary
Somatostatin receptor(SSTR) was expressed in neuroendocrine tumor cells and SSTR-targeting molecular imaging(68Ga-DOTATATE PET/CT) could be a promising technique to evaluate the primary tumor and meta...
Detailed Description
Neuroendocrine tumor(NET)can be derived from endocrine glands, endocrine tissues and endocrine cells from any parts of body. Due to its occult onset and heterogeneity, it is hard to be detected by con...
Eligibility Criteria
Inclusion
- suspected or confirmed untreated NET patients previously performed 18F-FDG PET/CT signed written consent.
Exclusion
- pregnancy breastfeeding known allergy against TATE any medical condition that in the opinion of the investigator, may significantly interfere with study compliance.
Key Trial Info
Start Date :
April 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04041882
Start Date
April 1 2014
End Date
January 30 2022
Last Update
August 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine, Peking Union Medical College Hopital, Chinese Academy of Medical Science
Beijing, China